We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




HDL Cholesterol Measurement Unaffected by Serum Amyloid A

By LabMedica International staff writers
Posted on 25 Feb 2019
High-density lipoprotein cholesterol (HDL) is known as the anti-atherogenic lipoprotein. More...
Epidemiological studies have shown that low plasma concentrations of HDL are associated with an increased risk of cardiovascular events. HDL-cholesterol (HDL-C) is the only standardized parameter available to estimate the plasma HDL concentration.

Serum amyloid A (SAA) is a highly conserved, acute phase protein that is predominantly synthesized by the liver. During acute inflammation, SAA concentrations in the serum can increase to up to 1000-fold of the basal levels. Under these conditions, SAA displaces apolipoprotein A-I (apoA-I) in HDL and becomes the major apolipoprotein of circulating HDL.

Clinical biochemists from the Tokyo Medical and Dental University (Tokyo, Japan) and their colleagues obtained anonymized serum samples with various C-reactive protein (CRP) concentrations from 248 patients without clinically apparent liver disease. The SAA concentration of the serum samples were measured by latex agglutination turbidimetric immunoassay, and the serum samples were stratified into three groups, based on their SAA concentrations: low SAA (SAA ≤ 8 μg/mL, n = 94), middle SAA (8 < SAA ≤ 100 μg/mL, n = 37), and high SAA (SAA > 100 μg/mL, n = 117).

The team performed all assays on an automatic analyzer, JCA-BM8000 series. SAA and CRP were measured by the latex agglutination turbidimetric immunoassay using the LZ test ‘Eiken’ SAA and CRP-latexX2, respectively. HDL-C, low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triglyceride (TG) levels were determined using commercial assays. The evaluation of HDL particle size was done with whole lipoproteins isolated by ultracentrifugation from randomly selected serum samples of patients with low or high SAA concentrations and was dialyzed against PBS and subjected to native-gel electrophoresis (native-PAGE) using 8% polyacrylamide gels.

The team reported that HDLs obtained from patients with low SAA concentrations were separated into their general particle sizes and classified as HDL2 and HDL3 by native-gel electrophoresis. On the other hand, HDLs obtained from patients with high SAA concentrations occasionally showed distributions different from the typical sizes of HDL2 and HDL3, such as extremely small or large particles. Nevertheless, HDL-C concentrations measured using the homogeneous assay was strongly correlated with those measured using the ultracentrifugation method, regardless of the SAA concentrations. However, the ratios of HDL-C concentrations obtained by the homogeneous assay to those obtained by the ultracentrifugation method for patients with high SAA concentrations were significantly lower than those of patients with low SAA concentrations.

The authors concluded that structural diversity, such as HDL particle size and SAA distribution, was observed in HDLs obtained from patients with inflammation; however, the HDL-C values measured by homogeneous assay were consistent with those obtained by ultracentrifugation method, regardless of SAA concentrations, an indicator of the presence or absence of inflammation. The study was published in the January 2019 issue of the journal Clinical Biochemistry.

Related Links:
Tokyo Medical and Dental University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.